AstraZeneca has announced positive high level results from its pivotal Phase III MIRANDA trial, marking the third successful late stage study for tozorakimab. The trial demonstrated that this potential first in class biologic significantly reduced the annualized rate of moderate to severe exacerbations in patients with chronic obstructive pulmonary disease (COPD). The benefits were observed in both the primary population of former smokers and the overall population, which included current smokers across various stages of lung function severity.

A differentiated mechanism of action

Tozorakimab is a monoclonal antibody that targets interleukin 33 (IL 33). Unlike other therapies, it uniquely inhibits the signaling of both the reduced and oxidized forms of IL 33. This dual action is designed to address the underlying drivers of COPD by reducing inflammation and disrupting the cycle of mucus dysfunction. In the MIRANDA study, patients received a 300mg dose of tozorakimab or a placebo every two weeks on top of their existing standard of care.

Clinical urgency and evidence

These results follow the successful OBERON and TITANIA trials, which evaluated tozorakimab at four week dosing intervals. Frank Sciurba, MD, Chief Investigator of the LUNA program, noted the critical need for such advancements:

“These results add to the growing body of evidence that indicates tozorakimab delivered meaningful clinical benefits for COPD patients who urgently need new treatment options. Up to half of patients today still experience exacerbations even when taking standard-of-care inhaled therapies, putting them at risk of serious health consequences including hospitalisation and even death.”

Research and development outlook

Sharon Barr, Executive Vice President of BioPharmaceuticals R&D at AstraZeneca, emphasized the therapy’s unique approach:

“These data further demonstrate tozorakimab’s exciting potential as a first-in-class biologic with a truly differentiated mechanism of action that inhibits the signalling of the reduced and oxidised forms of IL-33 to address underlying drivers of COPD. We look forward to sharing the data with regulators and the scientific community as soon as possible.”

Safety and global impact

Tozorakimab was generally well tolerated throughout the trial, maintaining a safety profile consistent with previous clinical studies. COPD currently affects nearly 400 million people worldwide and remains the third leading cause of death globally. With more than half of patients experiencing exacerbations despite inhaled treatments, tozorakimab represents a major potential shift in the management of the disease. Beyond COPD, the biologic is also being investigated for use in severe viral lower respiratory tract disease and asthma.